- Home
- BMRA vs PPBT Comparison
BMRA vs PPBT Comparison
Compare BMRA & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- PPBT
- Stock Information
- Founded
- BMRA 1971
- PPBT 2010
- Country
- BMRA United States
- PPBT Israel
- Employees
- BMRA N/A
- PPBT N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- PPBT Health Care
- Exchange
- BMRA Nasdaq
- PPBT Nasdaq
- Market Cap
- BMRA 8.2M
- PPBT 7.4M
- IPO Year
- BMRA N/A
- PPBT N/A
- Fundamental
- Price
- BMRA $2.45
- PPBT $0.71
- Analyst Decision
- BMRA
- PPBT Strong Buy
- Analyst Count
- BMRA 0
- PPBT 1
- Target Price
- BMRA N/A
- PPBT $33.00
- AVG Volume (30 Days)
- BMRA 30.0K
- PPBT 21.8M
- Earning Date
- BMRA 10-14-2025
- PPBT 11-14-2025
- Dividend Yield
- BMRA N/A
- PPBT N/A
- EPS Growth
- BMRA N/A
- PPBT N/A
- EPS
- BMRA N/A
- PPBT N/A
- Revenue
- BMRA $4,884,000.00
- PPBT N/A
- Revenue This Year
- BMRA N/A
- PPBT N/A
- Revenue Next Year
- BMRA N/A
- PPBT N/A
- P/E Ratio
- BMRA N/A
- PPBT N/A
- Revenue Growth
- BMRA N/A
- PPBT N/A
- 52 Week Low
- BMRA $2.08
- PPBT $0.53
- 52 Week High
- BMRA $10.16
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- BMRA 33.88
- PPBT 45.98
- Support Level
- BMRA $2.36
- PPBT $0.71
- Resistance Level
- BMRA $2.56
- PPBT $0.89
- Average True Range (ATR)
- BMRA 0.12
- PPBT 0.13
- MACD
- BMRA -0.02
- PPBT 0.01
- Stochastic Oscillator
- BMRA 13.64
- PPBT 17.37
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.